A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
-
BUSINESS Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
-
REGULATORY As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
October 2, 2023
-
REGULATORY Japan Seeking Solutions as Lab Monkey Shortage, Price Surge Threaten to Stymie Drug Development
October 2, 2023
-
REGULATORY Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
-
REGULATORY As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access
September 28, 2023
-
REGULATORY Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
-
BUSINESS Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
-
REGULATORY Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
-
REGULATORY Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
-
ACADEMIA Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
-
BUSINESS LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
September 22, 2023
-
REGULATORY Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
-
BUSINESS Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief
September 21, 2023
-
REGULATORY Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
-
REGULATORY MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
-
REGULATORY Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
-
ORGANIZATION JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
September 19, 2023
-
REGULATORY Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
-
REGULATORY New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
September 15, 2023
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…